According to filings with the U.S. Securities and Exchange Commission, Neonc Technologies is raising up to $18,688,064.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Neonc Technologies
NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the bodys Blood-Brain Barrier (BBB). Using NeOncs formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provide patients with potentially more effective treatments.

To learn more about Neonc Technologies, visit http://neonctech.com/
Neonc Technologies Linkedin Page: https://www.linkedin.com/company/neonctechnologiesholdingsinc/

Contact:
Thomas Chen, Chief Executive Officer
310-663-7831

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.